Antares Pharma, Inc. (ATRS)

[Polack]

Wall Street's Best Hidden Stocks

http://www.fool.com/investing/general/2011/08/04/wall-streets-best-hidden-stocks.aspx

From the Article:

"Wall Street's Best Hidden Stocks
By Rich Duprey | More Articles
August 4, 2011 | Comments (0)

When asked for the secret of his success, baseball player Wee Willie Keeler replied, "Hit 'em where they ain't." What worked for Willie at the plate applies equally well in investing. 

Seeking stocks that others ignore, shun, or simply forget gives individual investors like you an edge over the professionals. When Wall Street turns a blind eye, you have a chance to get in before these stocks get discovered -- or rediscovered -- and start taking off. 

Below, we'll check out companies with only a handful of analyst coverage and then pair our list with the opinions of the Motley Fool CAPS community. A stock that garners CAPS' top ratings but hasn't yet caught analysts' attention could be your next home-run investment. 

Stock

CAPS Rating (out of 5)

Wall Street Picks

Estimated EPS Growth Next Year

Antares Pharma (NYSE: AIS  ) **** 1 800%


Sources: Yahoo! Finance, Motley Fool CAPS.

Remember, without much analyst support, you'll have to do your own scouting to see whether these stocks deserve a spot on your portfolio's roster. Don't just buy or sell them based solely on their appearance here. 

Moving the needle
Certainly, the decision by Watson Pharmaceuticals (NYSE: WPI  ) to market Antares Pharma's incontinence gel Anturol is going to be one of those developments that transforms the specialty pharma into a big growth stock. With 30 million Americans estimated to suffer from overactive bladder syndrome (half of whom are too embarrassed to discuss it), Antares estimates that there's a $2 billion market to be addressed.

Equally transformative, though, will be its multiproduct deal with Teva Pharmaceutical (Nasdaq: TEVA  ) for its various drug-injector technologies (Antares sports an interesting mix of needle and needle-less injectors, as well as topical gel-delivery systems like Anturol). In particular, Teva has two abbreviated new drug applications before the FDA for Antares' self-injectable Vibex platform, one using epinephrine and the other an undisclosed drug, both of which could be considered by the end of this year. (Teva also uses Antares' needle-free injection system for its human growth hormone therapy.)

That could be why 96% of the CAPS community rating the pharmaceutical believe it will outperform the broad market averages. Let us know on the Antares Pharma CAPS page whether you think this is an investment worth injecting into our portfolio."